Pharming Group (NASDAQ:PHAR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pharming Group (NASDAQ:PHAR) to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently weighed in on the company. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Zacks Research cut Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Tuesday, September 22nd. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Pharming Group presently has an average rating of “Hold” and an average target price of $38.67.

Pharming Group Stock Performance

PHAR stock opened at $11.90 on Friday. The firm has a 50 day moving average of $10.69 and a two-hundred day moving average of $13.92. Pharming Group has a 12 month low of $9.11 and a 12 month high of $21.34. The company has a market capitalization of $842.28 million, a price-to-earnings ratio of 99.17 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. As a group, equities analysts anticipate that Pharming Group will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.